Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study
Sandra L. Wong(Dartmouth–Hitchcock Medical Center), Daniel G. Coit(Memorial Sloan Kettering Cancer Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Stanley P. L. Leong(California Pacific Medical Center), James S. Goydos(Rutgers, The State University of New Jersey), Omgo E. Nieweg(The University of Sydney), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Grant W. Carlson(Emory University), Kelly M. McMasters(University of Louisville), Adam I. Riker(University of South Florida), Michael S. Sabel(Michigan Cancer Research Consortium), Haim Gutman(Tel Aviv University), A. Benedict Cosimi(Massachusetts General Hospital), Donald L. Morton(University of California, Los Angeles), Douglas S. Tyler(University of North Carolina at Chapel Hill), Douglas S. Reintgen(Allegheny General Hospital), John F. Thompson(Melanoma Institute Australia)
Cited by 166
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k